<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>jmedicalcasereports</PublisherName>
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 2; Issue 5</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>(Sep-Oct, 2021)</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Severe and Early Hepatic Failure in A Neonate: A New CFTR Mutation Associated with Medium-Chain Acyl-CoA Deficiency</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1</FirstPage>
      <LastPage>5</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Silvana El</FirstName>
          <LastName>Zoghbi</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Constance</FirstName>
          <LastName>Barazzone-Argiroffo</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Thierry</FirstName>
          <LastName>Nouspikel</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Anne-Laure</FirstName>
          <LastName>Rougemont</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Laetitia-Marie</FirstName>
          <LastName>Petit</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Anne</FirstName>
          <LastName>Mornand</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>We report a case of an infant who presented at one month of age with severe malnutrition and neonatal cholestasis. He was born at term in Romania where no cystic fibrosis screening was performed. He rapidly developed cirrhosis and portal hypertension associated with severe pulmonary involvement leading to death at six months of age. Cystic fibrosis was diagnosed based on sweat test and genetic exam. Molecular analysis for CFTR gene identified a new undescribed c.1853_1863del deletion and a SERPINA 1 mutation corresponding to PiS phenotype. Concomitantly, we evidenced medium-chain acyl-CoA deficiency (MCAD). To our knowledge, this association was never described and might be responsible for rapid clinical deterioration and early hepatobiliary complications.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Cystic Fibrosis,SERPINA 1 Mutation,MCAD,Neonate,Hepatic Failure,CFTR Gene</Keywords>
      <URLs>
        <Abstract>https://www.jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=13319&amp;title=Severe and Early Hepatic Failure in A Neonate: A New CFTR Mutation Associated with Medium-Chain Acyl-CoA Deficiency</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL. Genetic modifiers of liver disease in cystic fibrosis, JAMA 2019; 302: 1076-1083.&#13;
&#13;
Boand;euml;lle PY, Debray D, Guillot L, Clement A, Corvol H. Cystic Fibrosis Liver Disease:Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology 2009; 69: 1648-1656.&#13;
&#13;
Debray D, Narkewicz MR, Bodewes FA, Colombo C, Housset C, De Jonge HR, Jonker JW, Kelly DA, Ling SC, Poynard T, Sogni P. Cystic Fibrosis-related Liver Disease:Research Challenges and Future Perspectives. J Pediatr Gastroenterol Nutr 2017; 65: 443-448.&#13;
&#13;
Leeuwen L, Fitzgerald DA, Gaskin KJ. Liver disease in cystic fibrosis. Paediatr Respir Rev 2014; 15: 69-74.&#13;
&#13;
Merritt 2nd JL and Chang IJ. and;#39;Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiencyand;#39;, in GeneReviews® eds Ardinger MP, Adam HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al. (Seattle: (WA): University of Washington) 2019; pp: 1993–2020.&#13;
&#13;
Nagra N and Dang S. Protein Losing Enteropathy. StatPearls Publishing, Florida 2021.&#13;
&#13;
Rowntree RK and Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet 2003; 67: 471–485.&#13;
&#13;
Stonebraker JR, Ooi CY, Pace RG, Corvol H, Knowles MR, Durie PR, Ling SC. Features of severe liver disease with portal hypertension in patients with cystic fibrosis. Clin Gastroenterol Hepatol 2016; 14: 1207-1215.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>